In order to investigate these hypotheses further, we explored the clinical outcomes of the ALK‐ and ROS1‐rearranged NSCLC populations treated with crizotinib (the first licensed ALK and ROS1 inhibitor) within the industry‐sponsored phase I trial, PROFILE 1001, according to the presence or absence of anticoagulant use as a surrogate for a thromboembolic phenotype. Here, ROS1 is linked to non-small cell lung carcinoma.